LncRNA LINC01339 Hinders the Development of Wilms' Tumor via MiR-135b-3p/ADH1C Axis.

IF 2 4区 医学 Q3 ENDOCRINOLOGY & METABOLISM Hormone and Metabolic Research Pub Date : 2024-03-01 Epub Date: 2023-10-27 DOI:10.1055/a-2184-8945
Yang Yu, Yanfei Liu
{"title":"LncRNA LINC01339 Hinders the Development of Wilms' Tumor via MiR-135b-3p/ADH1C Axis.","authors":"Yang Yu, Yanfei Liu","doi":"10.1055/a-2184-8945","DOIUrl":null,"url":null,"abstract":"<p><p>Wilms' tumor is a malignant renal cancer that arises within the pediatric urinary system. This study intended to investigate how a novel long non-coding RNA LINC01339 functions in the pathogenesis of Wilms' tumor. An elevated miR-135b-3p expression as well as reduced levels of LINC01339 and ADH1C were observed in Wilms' tumor. LINC01339 mediated ADH1C expression by directly binding to miR-135b-3p. The enforced LINC01339 or ADH1C markedly hindered cell growth and migration in Wilms' tumor. The LINC01339 overexpression also repressed the growth of Wilms' tumors in vivo, whereas miR-135b-3p overexpression exerted the opposite effects on Wilms' tumor cells in vitro. Additionally, upregulating miR-135b-3p reversed LINC01339's effects on the cellular processes of Wilms' tumor cells, whereas ADH1C overexpression offset the cancer-promoting influence of miR-135b-3p upregulation on Wilms' tumor progression. Therefore, LINC01339 prevents Wilms' tumor progression by modulating the miR-135b-3p/ADH1C axis. Our findings substantiate that the LINC01339/miR-135 b-3p/ADH1C regulatory axis has potential to be a target for the treatment of Wilms' tumor.</p>","PeriodicalId":12999,"journal":{"name":"Hormone and Metabolic Research","volume":null,"pages":null},"PeriodicalIF":2.0000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hormone and Metabolic Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1055/a-2184-8945","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/10/27 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Wilms' tumor is a malignant renal cancer that arises within the pediatric urinary system. This study intended to investigate how a novel long non-coding RNA LINC01339 functions in the pathogenesis of Wilms' tumor. An elevated miR-135b-3p expression as well as reduced levels of LINC01339 and ADH1C were observed in Wilms' tumor. LINC01339 mediated ADH1C expression by directly binding to miR-135b-3p. The enforced LINC01339 or ADH1C markedly hindered cell growth and migration in Wilms' tumor. The LINC01339 overexpression also repressed the growth of Wilms' tumors in vivo, whereas miR-135b-3p overexpression exerted the opposite effects on Wilms' tumor cells in vitro. Additionally, upregulating miR-135b-3p reversed LINC01339's effects on the cellular processes of Wilms' tumor cells, whereas ADH1C overexpression offset the cancer-promoting influence of miR-135b-3p upregulation on Wilms' tumor progression. Therefore, LINC01339 prevents Wilms' tumor progression by modulating the miR-135b-3p/ADH1C axis. Our findings substantiate that the LINC01339/miR-135 b-3p/ADH1C regulatory axis has potential to be a target for the treatment of Wilms' tumor.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
LncRNA LINC01339通过MiR-135b-3p/ADH1C轴抑制威尔姆斯肿瘤的发展。
肾母细胞瘤是一种发生在儿童泌尿系统内的恶性癌症。本研究旨在探讨一种新的长非编码RNA LINC01339在威尔姆斯肿瘤发病机制中的作用。在威尔姆斯肿瘤中观察到miR-135b-3p表达升高以及LINC01339和ADH1C水平降低。LINC01339通过直接结合miR-135b-3p介导ADH1C表达。LINC01339或ADH1C可明显阻碍威尔姆斯肿瘤细胞的生长和迁移。LINC01339过表达在体内也抑制了Wilms肿瘤的生长,而miR-135b-3p过表达在体外对Wilms肿瘤细胞产生了相反的作用。此外,上调miR-135b-3p逆转了LINC01339对威尔姆斯肿瘤细胞的细胞过程的影响,而ADH1C的过度表达抵消了miR-135b-3 p上调对威尔姆斯的肿瘤进展的致癌影响。因此,LINC01339通过调节miR-135b-3p/ADH1C轴来预防Wilms的肿瘤进展。我们的发现证实了LINC01339/miR-135 b-3p/ADH1C调控轴有可能成为治疗威尔姆斯肿瘤的靶点。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Hormone and Metabolic Research
Hormone and Metabolic Research 医学-内分泌学与代谢
CiteScore
3.80
自引率
0.00%
发文量
125
审稿时长
3-8 weeks
期刊介绍: Covering the fields of endocrinology and metabolism from both, a clinical and basic science perspective, this well regarded journal publishes original articles, and short communications on cutting edge topics. Speedy publication time is given high priority, ensuring that endocrinologists worldwide get timely, fast-breaking information as it happens. Hormone and Metabolic Research presents reviews, original papers, and short communications, and includes a section on Innovative Methods. With a preference for experimental over observational studies, this journal disseminates new and reliable experimental data from across the field of endocrinology and metabolism to researchers, scientists and doctors world-wide.
期刊最新文献
Denosumab for Management of Hypercalcemia in Primary Hyperparathyroidism. Improvement of Bone Metabolism in Prepubertal Girls with Turner Syndrome Following Long-term Pegylated Growth Hormone Treatment. Meta-Analysis and Network Analysis Differentially Detect Various Pro-Inflammatory Mediators and Risk Factors for Type 2 Diabetes in the Elderly. Cross-Talk Between Thyroid Disorders and Nonalcoholic Fatty Liver Disease: From Pathophysiology to Therapeutics. Dysregulation of miR-335-5p in People with Obesity and its Predictive Value for Metabolic Syndrome.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1